HC Wainwright Reaffirms “Buy” Rating for Akebia Therapeutics (NASDAQ:AKBA)
HC Wainwright restated their buy rating on shares of Akebia Therapeutics (NASDAQ:AKBA – Free Report) in a research report released on Friday,Benzinga reports. The brokerage currently has a $7.50 target price on the biopharmaceutical company’s stock. Separately, StockNews.com lowered Akebia Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, March […]
HC Wainwright restated their buy rating on shares of Akebia Therapeutics (NASDAQ:AKBA – Free Report) in a research report released on Friday,Benzinga reports. The brokerage currently has a $7.50 target price on the biopharmaceutical company’s stock. Separately, StockNews.com lowered Akebia Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, March […]
